Friday, 20 Oct 2017

News

Romosuzumab Outperforms Teriparatide in Post-Bisphosphonate Osteoporosis

The STRUCTURE trial results have been reported in Lancet and have shown that after 12 months of therapy, romosozumab (ROMO) had superior gains in bone mineral density (BMD) compared to teriparatide (TER) in women with postmenopausal osteoporosis who have previously taken bisphosphonate therapy.

Lupus Hospitalizations are Common

Patients with systemic lupus erythematosus (SLE) incur substantial morbidity and complications that may lead to hospitalizations and increased cost of lupus care. Researchers from the University Health Network in Toronto have published a review of SLE hospitalizations showing thta while commone (for either infection or lupus activity), only 2.8% of hospitalizations resulted in death.

One-Third of Americans Took Opioids in 2015

 In the wake of the well-publicized "opioid epidemic", researchers report in the Annals of Internal Medicine (online July 31) that more than one third of U.S. adults were prescribed opioids in 2015 and that misuse remains a major problem. (Citation source http://buff.ly/2vkd8au)

CDC: Outbreak of Arthrocentesis Related Septic Arthritis Cases in New Jersey

In March 2017, an outbreak of 41 cases of septic arthritis associated with intra-articular injections administered at an single outpatient practice occurred in New Jersey. A public health investigation identified multiple breaches of recommended infection prevention practices during the preparation and administration of PBP products. The intraarticular injections were done using fluoroscopic visualization. The CDC has reported the results of its investigation.

August 2nd AAC Meeting: FDA Concerns Over Sirukumab Deaths

On August 2, the US Food and Drug Administration (FDA) will convene a hearing of the Arthritis Advisory Committee (AAC) to review the safety of the novel IL-6 inhibitor, sirukumab, being developed by Janssen (Johnson & Johnson). Specifically, FDA reviewers have concerns over the number of deaths on sirukumab compared to those receiving placebo.

NEJM: Actemra Effective in Giant Cell Arteritis

On May 22, Genentech received FDA approval for the use of subcutaneous (sc) tocilizumab (TCZ) in patients with giant cell arteritis (GCA) – also known as temporal arteritis. This new indication is largely based on the landmark GiACTA study presented at the annual ACR meeting in November 2016. The results are now published in the New England Journal of Medicine (NEJM). 

The RheumNow Week in Review – 28 July 2017

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:

Denosumab Increases Trabecular Bone

Bone mineral density (BMD) measurement vie DEXA scan commonly used to assess bone density and fracture risk in postmenopausal osteoporosis provides us with approximate assessment of bone health while lacking sensitivity in vertebral fracture risk prediction. Newer techniques, such as the trabecular bone score (TBS), provide better insight into bone microarchitecture - an important factor for fragility fracture.

Biosimilar Pricing Wars Have Begun

Despite the approval of four anti-TNF biosimilars in 12 months, their introduction into the U.S. market has been slow and - until now - with paultry discounts compared to their introduction throughout Europe, where discounts averaged 50% and were as high as 70% (compared to the price of Remicade).

Increased Pulmonary Embolism Risk in Lupus Patients

Systemic lupus erythematosus (SLE) poses numerous vascular risks, many of which are thought to be autoantibody mediated.

A retrospective population-based analysis was done to determine the association of SLE and plumonary embolism (PE) using the National Hospital Discharge Survey data, a representative sample of hospital discharges throughout the United States.

Tubulointerstitial Damage in Lupus Predicts ESRD Progression

The presence of tubulointerstitial damage (TID) may provide a potential window for early intervention in lupus nephritis (LN) to ward off end-stage renal disease (ESRD), according to a data analysis.

Baricitinib Derailed by FDA Review

Eli Lilly and Co disclosed today that upon further discussions with the US Food and Drug Administration (FDA) there would be a delay in further regulatory decisions regarding baricitinib, a JAK inhibitor, that is being developed for use in rheumatoid arthritis (RA).